Vor Biopharma(NASDAQ) VOR

Vor Bio creates medicines for people with autoimmune diseases where the body attacks itself. These treatments help by blocking specific blood signals that cause painful swelling and muscle weakness. The company focuses on helping patients manage rare conditions that affect daily movement and organ health.

The Product Pipeline

• Telitacicept: A fusion protein that blocks two specific molecules called BAFF and APRIL to reduce harmful immune responses in the body.
• Myasthenia Gravis Program: A treatment in Phase 3 clinical trials for a chronic condition that causes life-threatening muscle weakness.
• Sjogren’s Disease Program: A medicine currently being tested in global trials to treat dry mouth, dry eyes, and systemic organ damage.

A Major Strategic Pivot

• In June 2025, the company gained exclusive rights to develop and sell telitacicept outside of Greater China through a deal with RemeGen.
• The company announced a winddown of its original cancer-focused clinical and manufacturing operations in May 2025.
• During August and September 2025, Vor Bio sold intellectual property related to its previous programs, including trem-cel and VCAR33, to third-party buyers.
• In March 2026, the company agreed to sell common stock to TCGX for approximately $75 million in gross proceeds.

What Makes Vor Bio Stand Out

Vor Bio uses a dual-inhibition approach that targets two different signaling proteins to control overactive B cells more effectively than single-target therapies. The company also benefits from regulatory advantages, including Orphan Drug and Fast-Track designations from the FDA for its lead programs.

Key Financial Performance

• Net income reached $1.7 billion in Q4 2025, up from a loss of $30.7 million in Q4 2024.
• Operating income was a loss of $36 million in Q4 2025, which deepened by 14.8% compared to the prior year.
• Free cash flow was negative $23.1 million in Q4 2025, an improvement of 4.2% over the same period in 2024.
• Gross profit was negative $23,000 in Q4 2025, narrowing the loss by 97.3% from the previous year.

The Bottom Line

Vor Bio has transformed from a cancer-focused research firm into a clinical-stage developer of autoimmune therapies. This shift centers on a late-stage drug candidate that addresses rare conditions with few available treatment options.